Castle Biosciences Q4 revenue beats expectations

Castle Biosciences

26/02/2026 21:50

Overview

Diagnostics company's Q4 revenue rose 1%, beating analyst expectations

Company's core test reports increased 42% in Q4, driven by dermatologic and gastrointestinal tests

Outlook

Castle Biosciences anticipates 2026 revenue between $340 mln and $350 mln

Result Drivers

CORE TEST GROWTH - Total test reports for DecisionDx-Melanoma and TissueCypher increased 37% over 2024, with TissueCypher reports growing 86%

MEDICARE COVERAGE IMPACT - Revenue affected by change in DecisionDx-SCC Medicare coverage and discontinuation of IDgenetix

Company press release: ID:nGNX4v36tf

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$87.01 mln
$79.05 mln (7 Analysts)
Q4 Net Income
-$2.33 mln
Q4 Operating Expenses
$90.84 mln
Q4 Operating Income
-$3.83 mln
Q4 Pretax Profit
-$2.71 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Castle Biosciences Inc is $50.00, about 62.2% above its February 25 closing price of $30.83

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)